Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,001 public trials 2,038 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, not recruiting

A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis

NCT06752850

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Classic Hemophilia, +24 more
Locations
  • Sobi Investigational Site Milan, Italy
  • Sobi Investigational Site Naples, Italy
  • Sobi Investigational Site Rozzano, Italy
  • Sobi Investigational Site Oslo, Norway
View Trial Details
Active, not recruiting

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

NCT03075696

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • University of Michigan Ann Arbor, Michigan, United States
  • Washington University St Louis, Missouri, United States
  • Mount Sinai Medical Center New York, United States
  • MSKCC New York, United States
View all 34 locations
View Trial Details
Active, not recruiting

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

NCT05014646

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Atrium Health University City/LCI-University Charlotte, North Carolina, United States
View Trial Details
Active, not recruiting

Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

NCT01849263

Conditions
Grade 3a Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
  • Metro Minnesota Community Oncology Research Consortium Saint Louis Park, Minnesota, United States
View all 13 locations
View Trial Details
Active, not recruiting

Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

NCT04546620

Conditions
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Colchester General Hospital Colchester, Essex, United Kingdom
  • East Kent Hospitals NHS Foundation Trust Canterbury, Kent, United Kingdom
  • Monklands Hospital Airdrie, United Kingdom
  • Victoria Hospital Blackpool, United Kingdom
View all 33 locations
View Trial Details
Active, not recruiting

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

NCT04608318

Conditions
Chronic Lymphoid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • LKH-Universtitätsklinikum Graz Graz, Austria
  • Landeskrankenhaus - Universitätskliniken Innsbruck Innsbruck, Austria
  • Medizinische Universität Wien Vienna, Austria
  • Hanusch Krankenhaus Vienna, Austria
View all 181 locations
View Trial Details

Related conditions